Safety Study of a Less Invasive Liver Regeneration Therapy Using Cultured Autologous Bone Marrow-derived Mesenchymal Stem Cells for Decompensated Liver Cirrhotic Patient. - Safety Study of Liver Regeneration Therapy Using Cultured Autologous BMSCs.

Yamaguchi University Hospital0 个研究点目标入组 10 人开始时间: 2015年3月2日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients with a current history of malignant neoplasm. (2) Patients with gastroesophageal varices at risk of rupture. (3) Patients with renal insufficiency and a serum creatinine greater than or equal to 2 mg/dL. (4) Patients with a hemoglobin <8 g/dL, a platelet count <50,000/uL, or a prothrombin time <40%. (5) Patients with a performance status of 3 or 4. (6) Patients who refuse to consent to allogeneic blood transfusion. (8) Women who are pregnant. (9) Patients with a current or previous severe allergic reaction to anesthesia. (10) Patients with a current or previous severe allergic reaction to a contrast agent. (11) Patients with a current or previous severe allergic reaction to beef, cow milk. (12) Patients who had an experience with other cell therapy or other clinical study of cell therapy. (13) Any patient deemed unsuitable for study inclusion by their attending physician.

发起方